^
    Back
    Association details:
    Biomarker:ESR1 mutation + HR positive
    Cancer:HER2 Negative Breast Cancer
    Drug:Orserdu (elacestrant) (Selective estrogen receptor degrader)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ASCO.org
    Title:

    Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update

    Published date:
    05/17/2023
    Excerpt:
    For patients with prior CDK4/6 inhibitor treatment and a detectable ESR1 mutation, options include elacestrant, or other ET either alone or in combination with targeted agents such as alpelisib (for PIK3CA-mutated tumors) or everolimus.
    DOI:
    10.1200/JCO.23.00638
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    03/23/2023
    Excerpt:
    Invasive Breast Cancer….Biomarkers Associated with FDA-Approved Therapies….HR-positive/HER2-negative…ESR1 mutation…Elacestrant…Category 2A…Other recommended regimen